Cytek Biosciences Q2 2024 GAAP EPS $(0.08) Misses $(0.03) Estimate, Sales $46.617M Miss $49.526M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cytek Biosciences (NASDAQ:CTKB) reported Q2 2024 GAAP EPS of $(0.08), missing the $(0.03) estimate by 166.67%. Sales were $46.617M, missing the $49.526M estimate by 5.87% and down 6.19% from last year.
August 06, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cytek Biosciences reported Q2 2024 GAAP EPS of $(0.08), missing the $(0.03) estimate by 166.67%. Sales were $46.617M, missing the $49.526M estimate by 5.87% and down 6.19% from last year.
The significant miss on both EPS and sales estimates, along with a year-over-year decline in sales, is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100